Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update
Femasys Inc. (NASDAQ: FEMY) reported key developments in its latest press release, highlighting accelerated enrollment in the FemaSeed® trial focusing on male factor infertility and commercial availability of FemCerv®. The company plans to file an Investigational Device Exemption (IDE) for FemBloc® in Q1 2023. Financial results showed revenue growth from FemVue® but an increase in net loss, which reached $2.98 million for Q3 2022. R&D and G&A expenses rose significantly, impacting profitability. Cash reserves decreased from $24.78 million at year-end 2021 to $16.01 million by September 30, 2022.
- Accelerated enrollment in FemaSeed® trial targeting male factor infertility.
- Commercial launch of FemCerv®, enhancing product portfolio.
- FemVue® sales increased by 28.9% in Q3 2022, parallel to a 36.9% rise in U.S. sales.
- Net loss increased to $2.98 million in Q3 2022 compared to $2.26 million in Q3 2021.
- General and administrative expenses rose by 28.3% in Q3 2022, largely due to increased costs.
- Research and development expenses surged 44.5% in Q3 2022, indicating high operational costs.
--FemaSeed® de novo trial enrollment accelerates with strategic trial design update to focus on male factor infertility--
--Company remains on track to file an Investigational Device Exemption (IDE) for a pivotal trial to support a Pre-Market Authorization (PMA) for FemBloc® in Q1 2023--
--FemCerv® now commercially available with FemCath™ launch expected by year-end--
ATLANTA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the third quarter and nine months ended September 30, 2022 and provided a corporate update.
“We’ve hit multiple company milestones this past quarter, as well as further strengthened our management team in key functional areas,” said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. “Most notably, we completed enrollment in our Stage 2 trial of FemBloc® permanent birth control and strategically updated the FemaSeed® de novo trial design, accelerating enrollment for this important program. Approximately
Third Quarter and Recent Developments Related to Clinical Programs and Commercial Products
FemBloc
- In July, Femasys hosted a Key Opinion Leader (KOL) event in the wake of the overturn of Roe v. Wade, to discuss FemBloc. The webinar featured a presentation from key opinion leader, Paul D. Blumenthal, M.D., MPH, Professor of Obstetrics and Gynecology of The Stanford University Medical Center and discussion of the unmet need for women seeking permanent birth control options. Following the event, several media outlets reported on the topic, including CNN Business and other industry-focused publications.
- In October, the Company announced enrollment completion for its Stage 2 study of FemBloc®, a first-of-its-kind, nonsurgical, in-office solution in development for permanent birth control. The Stage 2 study is a prospective, multi-center, feasibility study (NCT04273594) validating the confirmation test required after FemBloc to determine procedure success by comparing an ultrasound approach to the traditional radiology approach. Femasys intends to continue follow-up to monitor the safety of the subjects for a total duration of approximately 68 months after the FemBloc procedure. Femasys remains on track to file an Investigational Device Exemption (IDE) for a pivotal trial to support a Pre-Market Authorization (PMA) in the first quarter of next year.
FemaSeed
- In October, the Company announced an updated study design for its FemaSeed® pivotal trial, which will now focus on couples experiencing male factor infertility. This update reflects a strategic decision to address this underserved infertility population with a goal of facilitating accelerated enrollment. The FemaSeed LOCAL de novo clinical trial is a prospective multi-center, unblinded study (NCT04968847) being conducted across centers in the United States requiring evaluation of up to 214 women undergoing 214 FemaSeed cycles due to male factor infertility. The primary endpoints of the study are to determine the effectiveness (pregnancy rate) and safety over a period of seven weeks post-FemaSeed procedure. The Company expects study enrollment to be completed in 2023.
FemCerv
- In September, the Company announced the commercial availability of FemCerv®, the first endocervical tissue sampler designed to improve tissue quality and quantity with minimal discomfort that is expected to be an improvement over the existing standard of care.
Third Quarter and Recent Corporate Highlights
- In July, the Company announced that Charles Larsen, a current member of Femasys’ Board of Directors, has been appointed to the role of non-executive Chair, replacing founder, president and chief executive officer, Kathy Lee-Sepsick. Mr. Larsen has served as a member of Femasys’ board of directors since October 2015.
- In September, the Company also announced the hiring of Michael Meier as Vice President of Sales and Marketing. Mr. Meier brings over 20 years of commercial experience to the Femasys team. He has a strong background in bringing innovative medical devices and diagnostic solutions to market as well as a proven track record of growing revenue by building and directing world-class sales and marketing teams. Mr. Meier has held various commercial leadership roles at medical device and diagnostic startups, in addition to fortune 500 companies including Hologic and Johnson & Johnson. Mr. Meier is leading sales and marketing efforts for all of Femasys’ commercial assets.
- In October, the Company announced the appointment of Christine Thomas, RAC, as senior vice president of regulatory and clinical affairs. Ms. Thomas has over 20 years of successful leadership in regulatory and clinical affairs, including global strategy development and operations, as well as executive responsibility for medical device companies such as GE Healthcare, Boston Scientific, Smiths Medical, and RTI Surgical. Ms. Thomas most recently served as head of regulatory solutions providing FDA focused consultant expertise at IQVIA MedTech, a large clinical research organization that provides solutions and services to support the needs of the medical device and in vitro diagnostics industry. Ms. Thomas is leading all regulatory and clinical efforts for the FemBloc and FemaSeed clinical programs at Femasys.
- In October, the Company’s management team attended the 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress in Anaheim, California. The Company also participated in various investor conferences this past quarter and recently. Upcoming conference participation by the Company will include the American Association of Gynecologic Laparoscopists (AAGL) from December 1st – 4th in Aurora, CO and the Piper Sandler 34th Annual Healthcare Conference from November 29th – December 1st in New York, NY.
Third Quarter 2022 Financial Results
- General and administrative expenses increased by
$307,700 , or28.3% , to$1,395,063 for the three months ended September 30, 2022 compared to$1,087,363 for the three months ended September 30, 2021. The net increase was largely due to an increase in salaries and related personnel costs, an increase in facility and other allocated overhead costs, and an increase in professional costs for legal and accounting. - Research and Development expenses increased by
$507,583 , or44.5% , to$1,648,160 for the three months ended September 30, 2022 compared to$1,140,577 for the three months ended September 30, 2021. The net increase was largely due to compensation and related personnel costs due to an increase in headcount and an increase in clinical-related costs to primarily support our clinical trials. - Sales the Company’s FemVue® product increased by
$77,875 , or28.9% , to$347,456 for the three months ended September 30, 2022 compared to$269,581 for the three months ended September 30, 2021 due to strong U.S. sales of FemVue. U.S. sales increased by$78,106 , or36.9% , for the three months ended September 30, 2022 compared to the same period last year, and U.S. units of FemVue sold increased by38.9% for the three months ended September 30, 2022 compared to the same period last year. International sales largely remained the same and were$57,814 and$58,045 for the three months ended September 30, 2022 and 2021, respectively. - Sales and marketing expenses increased by
$47,090 , or108.8% , to$90,374 for the three months ended September 30, 2022 compared to$43,284 for the three months ended September 30, 2021. The net increase was largely due to an increase in compensation and related personnel costs due to an increase in headcount. - Cost of sales increased by
$26,048 , or24.7% , to$131,451 for the three months ended September 30, 2022 compared to$105,403 for the three months ended September 30, 2021 which was largely due to our increase in U.S. FemVue sales. Gross margin percentage was62.2% for the three months ended September 30, 2022 compared to60.9% for the three months ended September 30, 2021, representing a1.3% change in our gross margin due to certain improvements we have started implementing in order to improve our manufacturing processes. - Net loss was
$2,982,843 or$0.25 per basic and diluted share attributable to common stockholders, primarily reflecting the factors noted above, for the three months ended September 30, 2022, compared to$2,259,701 , or$0.19 per basic and diluted share attributable to common stockholders, for the three months ended September 30, 2021. - Cash and cash equivalents as of September 30, 2022 and December 31, 2021, were
$16,005,650 and$24,783,029 , respectively.
Year to Date 2022 (Nine-Months) Financial Results
- General and administrative expenses increased by
$993,607 , or32.8% , to$4,024,356 for the nine months ended September 30, 2022 compared to$3,030,749 for the nine months ended September 30, 2021. The net increase was largely due to various additional costs associated with being a public company, including, an increase in salaries and related personnel and an increase in facility and other allocated overhead costs mainly for additional directors and officers insurance. - Research and Development expenses increased by
$1,511,680 , or49.9% , to$4,542,147 for the nine months ended September 30, 2022 compared to$3,030,467 for the nine months ended September 30, 2021. The net increase of$1,511,680 largely consists of an increase of compensation and related personnel costs primarily due to an increase in headcount and in clinical-related costs, to mainly support our clinical trials.
- Sales of the Company’s FemVue® product increased by
$46,612 , or5.0% , to$971,974 for the nine months ended September 30, 2022 compared to$925,362 for the nine months ended September 30, 2021. The$46,612 net increase was largely attributable to the increase in U.S. FemVue sales of$104,830 for the nine months ended September 30, 2022 compared to the same period last year. This amount was offset by the decrease of$58,218 in international sales for the nine months ended September 30, 2022 compared to the same period last year. U.S. units of FemVue sold increased by13.8% for the nine months ended September 30, 2022 compared to the same period last year. International sales decreased by33.4% and were$115,859 and$174,077 for the nine months ended September 30, 2022 and 2021, respectively. - Sales and marketing expenses increased by
$134,483 , or152.9% , to$222,414 for the nine months ended September 30, 2022 compared to$87,931 for the nine months ended September 30, 2021. This net increase was largely due to an increase in compensation and related personnel costs due to an increase in headcount and additional marketing costs mainly associated with our FemVue social media campaign earlier this year. - Cost of sales increased by
$50,407 , or16.5% , to$356,479 for the nine months ended September 30, 2022 compared to$306,072 for the nine months ended September 30, 2021. The net increase in cost of sales was mainly due to net increase in sales and increased production personnel labor and overhead costs applied to our cost of sales for the nine months ended September 30, 2022 compared to the same period last year. Gross margin percentage was63.3% for the nine months ended September 30, 2022 compared to66.9% for the nine months ended September 30, 2021. We expect to see improvement in our gross margin in the future as we are investing in equipment and tooling which will enable us to reduce labor in certain manufacturing processes and reduce material costs as well.
Net loss was$8,499,974 , or$0.72 per basic and diluted share attributable to common stockholders, primarily reflecting the factors noted above, for the nine months ended September 30, 2022, compared to$5,172,992 , or$1.04 per basic and diluted share attributable to common stockholders, for the nine months ended September 30, 2021.
| FEMASYS INC. | ||||||||||||
| Balance Sheets | ||||||||||||
| (unaudited) | ||||||||||||
| Assets | September 30, 2022 | December 31, 2021 | ||||||||||
| Current assets: | ||||||||||||
| Cash and cash equivalents | $ | 16,005,650 | 24,783,029 | |||||||||
| Accounts receivable, net | 183,130 | 84,258 | ||||||||||
| Inventory, net | 343,136 | 208,270 | ||||||||||
| Other current assets | 760,573 | 555,853 | ||||||||||
| Total current assets | 17,292,489 | 25,631,410 | ||||||||||
| Property and equipment, at cost: | ||||||||||||
| Leasehold improvements | 1,195,637 | 1,155,332 | ||||||||||
| Office equipment | 99,344 | 99,344 | ||||||||||
| Furniture and fixtures | 424,947 | 424,947 | ||||||||||
| Machinery and equipment | 2,434,524 | 2,261,793 | ||||||||||
| Construction in progress | 503,312 | 379,713 | ||||||||||
| 4,657,764 | 4,321,129 | |||||||||||
| Less accumulated depreciation | (3,115,551 | ) | (2,722,117 | ) | ||||||||
| Net property and equipment | 1,542,213 | 1,599,012 | ||||||||||
| Long-term assets: | ||||||||||||
| Lease right-of-use assets, net | 402,063 | 665,747 | ||||||||||
| Intangible assets, net of accumulated amortization | 5,759 | 25,093 | ||||||||||
| Other long-term assets | 789,616 | 655,418 | ||||||||||
| Total long-term assets | 1,197,438 | 1,346,258 | ||||||||||
| Total assets | $ | 20,032,140 | 28,576,680 | |||||||||
| (continued) | ||||||||||||
| FEMASYS INC. | ||||||||||||
| Balance Sheets | ||||||||||||
| (unaudited) | ||||||||||||
| Liabilities and Stockholders’ Equity | September 30, 2022 | December 31, 2021 | ||||||||||
| Current liabilities: | ||||||||||||
| Accounts payable | $ | 419,110 | 445,522 | |||||||||
| Accrued expenses | 649,615 | 603,787 | ||||||||||
| Clinical holdback - current portion | 36,238 | 18,947 | ||||||||||
| Note payable | 280,577 | 181,123 | ||||||||||
| Lease liabilities – current portion | 386,139 | 406,674 | ||||||||||
| Other | 36,037 | 36,037 | ||||||||||
| Total current liabilities | 1,807,716 | 1,692,090 | ||||||||||
| Long-term liabilities: | ||||||||||||
| Clinical holdback - long-term portion | 101,804 | 149,791 | ||||||||||
| Lease liabilities – long-term portion | 115,773 | 402,417 | ||||||||||
| Total long-term liabilities | 217,577 | 552,208 | ||||||||||
| Total liabilities | 2,025,293 | 2,244,298 | ||||||||||
| Commitments and contingencies | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common stock, | ||||||||||||
| 11,813,610 outstanding as of September 30, 2022; and 11,921,388 shares issued | ||||||||||||
| 11,804,165 outstanding as of December 31, 2021 | 11,931 | 11,921 | ||||||||||
| Treasury stock, 117,223 shares | (60,000 | ) | (60,000 | ) | ||||||||
| Warrants | 567,972 | 702,492 | ||||||||||
| Additional paid-in-capital | 108,727,253 | 108,418,304 | ||||||||||
| Accumulated deficit | (91,240,309 | ) | (82,740,335 | ) | ||||||||
| Total stockholders’ equity | 18,006,847 | 26,332,382 | ||||||||||
| Total liabilities and stockholders' equity | $ | 20,032,140 | 28,576,680 | |||||||||
| FEMASYS INC. | ||||||||||||||||||
| Statements of Comprehensive Loss | ||||||||||||||||||
| (unaudited) | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||||
| Sales | $ | 347,456 | 269,581 | 971,974 | 925,362 | |||||||||||||
| Cost of sales | 131,451 | 105,403 | 356,479 | 306,072 | ||||||||||||||
| Gross margin | 216,005 | 164,178 | 615,495 | 619,290 | ||||||||||||||
| Operating expenses: | ||||||||||||||||||
| Research and development | 1,648,160 | 1,140,577 | 4,542,147 | 3,030,467 | ||||||||||||||
| Sales and marketing | 90,374 | 43,284 | 222,414 | 87,931 | ||||||||||||||
| General and administrative | 1,395,063 | 1,087,363 | 4,024,356 | 3,030,749 | ||||||||||||||
| Depreciation and amortization | 139,597 | 144,399 | 426,480 | 449,211 | ||||||||||||||
| Total operating expenses | 3,273,194 | 2,415,623 | 9,215,397 | 6,598,358 | ||||||||||||||
| Loss from operations | (3,057,189 | ) | (2,251,445 | ) | (8,599,902 | ) | (5,979,068 | ) | ||||||||||
| Other income (expense): | ||||||||||||||||||
| Interest income, net | 80,373 | 1,649 | 109,572 | 1,957 | ||||||||||||||
| Other income | — | — | — | 821,515 | ||||||||||||||
| Interest expense | (6,005 | ) | (7,055 | ) | (9,622 | ) | (14,546 | ) | ||||||||||
| Other expense | (22 | ) | (2,850 | ) | (22 | ) | (2,850 | ) | ||||||||||
| Other income (expense), net | 74,346 | (8,256 | ) | 99,928 | 806,076 | |||||||||||||
| Net loss | $ | (2,982,843 | ) | (2,259,701 | ) | (8,499,974 | ) | (5,172,992 | ) | |||||||||
| Net loss attributable to common stockholders, basic and diluted | $ | (2,982,843 | ) | (2,259,701 | ) | (8,499,974 | ) | (5,172,992 | ) | |||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.25 | ) | (0.19 | ) | (0.72 | ) | (1.04 | ) | |||||||||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 11,813,610 | 11,799,720 | 11,810,289 | 4,996,680 | ||||||||||||||
About Femasys
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue®, is currently marketed in the United States. Femasys is also advancing FemCath™, an intrauterine catheter for selective evaluation of the fallopian tubes and FemCerv®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting. To learn more, visit www.femasys.com or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our product candidates; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com
Media
Karissa Cross, Ph.D.
LifeSci Communications
kcross@lifescicomms.com
Femasys Inc.
Investor Contact:
IR@femasys.com
Media Contact:
Media@femasys.com
FAQ
What are the key developments announced by Femasys Inc. in November 2022?
What was Femasys Inc.'s net loss for Q3 2022?
How did Femasys Inc.'s revenue change in Q3 2022?
What are the financial challenges Femasys Inc. is facing?
What is the focus of the FemaSeed® trial by Femasys Inc.?
